Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2022-09-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
北京德恒律师事务所关于东北制药集团股份有限公司2022年限制性股票激励计划预留部分限制性股票授予相关事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2022 restricted stock incentive plan of a company. It details the approval and authorization process, the conditions for the stock grant, and compliance with relevant laws and regulations. It is not a financial report, earnings release, or management discussion. It is a legal opinion related to a capital incentive plan, which is closely related to capital/financing activities. The document is not a brief announcement but a detailed legal opinion, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA). The best fitting category is Capital/Financing Update (CAP) because it concerns the legal aspects of a stock incentive plan, which is a capital-related matter.
2022-09-29 Chinese
2022年限制性股票激励计划预留授予激励对象名单（授予日）
Share Issue/Capital Change Classification · 95% confidence The document is a brief announcement from the board of Northeast Pharmaceutical Group Co., Ltd. regarding the reserved grant of restricted stock incentive plan for 2022. It lists the recipients and the number of shares granted. The content focuses on share-based incentive awards to management and key personnel, which relates to capital changes or share issuance. The document is short (418 characters) and does not contain financial statements or detailed analysis, so it is not a full financial report. It is not a report publication announcement or regulatory filing as it contains substantive information about share grants. Therefore, the best fitting category is Share Issue/Capital Change (SHA).
2022-09-29 Chinese
独立董事对公司第九届董事会第十一次会议相关事项发表的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on a specific board meeting agenda item related to the granting of restricted shares under an equity incentive plan. It references compliance with stock exchange listing rules and company articles, and provides an independent opinion on the legality and appropriateness of the equity incentive grant. The document is short (862 characters) and focuses on governance and board-level approval matters rather than financial results or detailed financial data. It does not contain financial statements or earnings data, nor is it a general announcement or report publication notice. This fits best under Board/Management Information (MANG), as it relates to board meeting matters and management decisions regarding equity incentives.
2022-09-29 Chinese
关于向激励对象授予预留部分限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the granting of reserved restricted shares under a stock incentive plan by Dongbei Pharmaceutical Group Co., Ltd. It details the approval process, the number of shares granted, the price, the recipients, and the legal and supervisory opinions. It is not a financial report, earnings release, or management discussion, but rather a formal announcement of a capital-related event involving share issuance to employees as part of an incentive plan. This fits the category of Share Issue/Capital Change (SHA), as it concerns the issuance of new shares under a stock incentive plan.
2022-09-29 Chinese
关于左炔诺孕酮片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the approval of a drug (left levonorgestrel tablets) passing a generic drug consistency evaluation by the National Medical Products Administration. It includes details about the drug, regulatory approval, impact on the company, and risk warnings. The document is short (935 characters) and is an announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or shareholder voting results. It is not a report but an announcement of regulatory and product approval information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-09-25 Chinese
关于公司产品上市申请获得批准的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a product listing application by the National Medical Products Administration (国家药品监督管理局). It details the approval of a chemical raw material drug product, its registration number, packaging, production enterprise, and the impact on the company. The document is short (1034 characters) and serves as an official announcement of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. It is not an annual report, earnings release, or any other financial filing. It is a regulatory announcement about product approval, which fits best under Regulatory Filings (RNS).
2022-09-22 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.